Pulse Biosciences to Report Fourth Quarter and Full Year 2017 Financial Results and Operational
Highlights
Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based
on its Nano-Pulse Stimulation platform, today announced that the Company will report fourth quarter and full year 2017 financial
results and operational highlights on Friday, March 16th, 2018. Pulse Biosciences management will host a conference call and
webcast at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing (844) 494-0190 (domestic) and (508) 637-5580
(international) using the conference ID# 1487908. The webcast of the conference call can be accessed live on the Investor Relations
section of the Pulse Biosciences website, www.pulsebiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a medical technology company developing a therapeutic tissue treatment based on the Nano-Pulse Stimulation
(NPS) platform, a proprietary cell signaling technology. NPS is a non-thermal, precise, focal, drug-free tissue treatment
technology that directly affects the cell membrane and intracellular structures to stimulate unique behaviors in cells. NPS can
initiate a cell death process that allows for the treatment of tissue cells with only a minimal inflammatory response, which
improves healing outcomes and supports the replacement of treated tissue cells with healthy tissue cells. In cancerous lesions, NPS
has been shown in preclinical models to induce immunogenic cell death (ICD), which exposes the unique antigens of the treated cells
to the immune system, results in the generation of cytotoxic T-cells and mounts an adaptive immune response. Pulse
Biosciences is investigating a variety of applications for its technology that exploits the technology’s unique biologic
effect, including immuno-oncology, dermatology, and veterinary medicine. More information is available at www.pulsebiosciences.com.
Investor Relations:
Pulse Biosciences, Inc.
Brian Dow
Sr. Vice President and Chief Financial Officer
IR@pulsebiosciences.com
or
The Trout Group
Mike Zanoni, 646-378-2924
mzanoni@troutgroup.com
or
Media:
Sam Brown, Inc.
Christy Curran, 615-414-8668
christycurran@sambrown.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180308006033/en/